Talpaz, Moshe

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 2,713

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 2,103

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,760

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics

Estrogen and related hormone effectsAdvanced Breast Cancer Therapies

Cited by 1,145

Integrative clinical genomics of metastatic cancer

Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 863

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 769

Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 277

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Cortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 208

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma

Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 164

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology

Cancer-related cognitive impairment studiesChronic Myeloid Leukemia Treatments

Cited by 160

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma

Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., & Kurzrock, R. (1997) · Annals of Internal Medicine

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 112

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 106

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Dasatinib dose management for the treatment of chronic myeloid leukemia

Talpaz, M., Saglio, G., Atallah, E., & Rousselot, P. (2018) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14